Source: http://www.google.com/patents/US5318591?dq=oakley+5,387,949
Timestamp: 2017-03-26 01:55:12
Document Index: 644103512

Matched Legal Cases: ['art 28', 'art 28', 'art 28', 'art 28', 'art 28', 'art 28']

Patent US5318591 - Implantable cardioverter-defibrillator having early charging capability - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsAn implantable cardioverter-defibrillator (ICD) provides a tiered therapy designed to automatically terminate tachyarrhythmias using the least aggressive therapy possible while reducing the "time-to-therapy." The tiered therapy first applies a first tier of therapy (e.g., antitachycardia). If unsuccessful,...http://www.google.com/patents/US5318591?utm_source=gb-gplus-sharePatent US5318591 - Implantable cardioverter-defibrillator having early charging capabilityAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS5318591 APublication typeGrantApplication numberUS 07/980,420Publication dateJun 7, 1994Filing dateNov 23, 1992Priority dateNov 23, 1992Fee statusPaidAlso published asEP0599588A2, EP0599588A3Publication number07980420, 980420, US 5318591 A, US 5318591A, US-A-5318591, US5318591 A, US5318591AInventorsJames D. Causey, III, Brian M. MannOriginal AssigneeSiemens Pacesetter, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (15), Referenced by (149), Classifications (6), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetImplantable cardioverter-defibrillator having early charging capability
US 5318591 AAbstract
An implantable cardioverter-defibrillator (ICD) provides a tiered therapy designed to automatically terminate tachyarrhythmias using the least aggressive therapy possible while reducing the "time-to-therapy." The tiered therapy first applies a first tier of therapy (e.g., antitachycardia). If unsuccessful, the tiered therapy next applies a second tier of therapy (e.g., cardioversion pulse with a pulse of moderate energy). If unsuccessful, the tiered therapy finally applies a third tier of therapy (e.g., a high energy pulse). So that more aggressive (higher energy) tiered therapies may be applied as early as possible following the failure of a less aggressive (lower energy) therapy, the ICD begins charging one or more high voltage capacitors of the ICD in parallel with the application of the less aggressive therapy, and/or in parallel with the verification interval immediately following a prior therapy attempt during which the ICD attempts to verify the successful termination of the tachyarrhythmia.
1. An implantable cardioverter-defibrillator (ICD) comprising:a sensing circuit that senses electrogram (EGM) signals through a sensing lead adapted to be coupled to a patient's heart; control logic and timing circuits that determine whether the EGM signals sensed by the sensing circuit is indicative of a tachyarrhythmia; a pulse generator that selectively generates stimulation pulses of a first energy in a prescribed pattern as controlled by the control logic and timing circuits, the stimulation pulse of the first energy being applied to the patient's heart through the sensing lead in an attempt to terminate the sensed tachyarrhythmia; a shocking electrode system adapted to be coupled to the patient's heart; and a cardioversion-defibrillation circuit that selectively generates stimulation pulses of a second energy as controlled by the control logic and timing circuits, the stimulation pulse of the second energy being applied to the patient's heart through the shocking electrode system in an attempt to terminate the sensed tachyarrhythmia, said cardioversion-defibrillation circuit including a high voltage output capacitor, a charging circuit that charges the high voltage output capacitor to a specified charge energy as controlled by the control logic and timing circuits, and a switching circuit that selectively connects the high voltage output capacitor to the shocking electrode system as controlled by the control logic and timing circuits in order to generate the stimulation pulses of said second energy; the control logic and timing circuits including means for terminating the sensed tachyarrhythmia in accordance with a tiered therapy, the tiered therapy including a first tier that applies the stimulation pulses of the first energy in response to sensing a given tachyarrhythmia, and a second tier that applies the stimulation pulses of the second energy immediately after determining that the first tier could not successfully terminate the tachyarrhythmia, and early charging means for controlling the charging circuit so that it charges the high voltage output capacitor to the specified charge energy before concluding the first tier of the tiered therapy;whereby in the event the first tiered therapy does not terminate the tachyarrhythmia, the second tier of therapy may be immediately applied without having to wait for the high voltage output capacitor to be charged. 2. The ICD as set forth in claim 1 wherein the cardioversion-defibrillation circuit further selectively generates stimulation pulses of a third energy as controlled by the control logic and timing circuits, said stimulation pulse of said third energy also being applied to the patient's heart through the shocking electrode system, and wherein the tiered therapy further includes a third tier that applies the stimulation pulses of the third energy immediately after determining that the second tier could not successfully terminate the tachyarrhythmia, and wherein the early charging means begins to charge the high voltage output capacitor before the conclusion of the second tier of the tiered therapy.
3. The ICD as set forth in claim 1 wherein the first tier of the tiered therapy includes a therapy phase and a verification phase, and wherein the early charging means controls the charging circuit to charge the high voltage output capacitor during the therapy phase of the first tier of the tiered therapy; whereby the second tier may be immediately applied as soon as a determination is made that the first tier was unsuccessful without having to wait for the high voltage output capacitor to be charged to the specified charge energy by the charging circuit.
4. The ICD, as set forth in claim 3, wherein the tiered therapy invoked by the control logic and timing circuits further includes a third tier that applies stimulation pulses of a third energy to the patient's heart through the shocking electrode system after determining that the second tier could not successfully terminate the tachyarrhythmia.
5. The ICD, as set forth in claim 4, wherein the control logic and timing circuits cause the charging circuit to charge the high voltage output capacitor to a selected one of two prescribed charge energies;a first of the prescribed charge energies corresponding to the second tier of the tiered therapy; and a second of the prescribed charge energies corresponding to the third tier of the tiered therapy; the control logic and timing circuits being configured to cause the charging circuit to charge the high voltage output capacitor to the second prescribed charge energy during the application of the second tier of the tiered therapy;whereby the third tier may be applied as soon as a determination is made that the second tier was unsuccessful without having to wait for the high voltage output capacitor to be charged to the second prescribed charge energy by the charging circuit. 6. The ICD as set forth in claim 1 wherein the first tier of the tiered therapy includes a therapy phase and a verification phase, and wherein the early charging means controls the charging circuit to charge the high voltage output capacitor during the verification phase of the first tier, said verification phase beginning at a time during which the EGM signals following the therapy phase of the first tier of the tiered therapy are being analyzed to determine if the first tier was successful in terminating the tachyarrhythmia; whereby the second tier may be applied as soon as a determination is made that the first tier was unsuccessful without having to wait for the high voltage output capacitor to be charged to the specified charge energy by the charging circuit.
7. The ICD, as set forth in claim 6, wherein the tiered therapy invoked by the control logic and timing circuits further includes a third tier that applies stimulation pulses of a third energy to the patient's heart through the shocking electrode system after determining that the second tier could not successfully terminate the tachyarrhythmia.
8. The ICD, as set forth in claim 7, wherein the control logic and timing circuits cause the charging circuit to charge the high voltage output capacitor to a selected one of two prescribed charge energies;a first of the prescribed charge energies corresponding to the second tier of the tiered therapy; and a second of the prescribed charge energies corresponding to the third tier of the tiered therapy; the control logic and timing circuits being configured to cause the charging circuit to charge the high voltage output capacitor to the second prescribed charge energy beginning at a time during which the EGM signals following application of the second tier of the tiered therapy are being analyzed to determine if the second tier was successful in terminating the tachyarrhythmia;whereby the third tier may be applied as soon as a determination is made that the second tier was unsuccessful without having to wait for the high voltage output capacitor to be charged to the second prescribed charge energy by the charging circuit. 9. An implantable cardioverter-defibrillator (ICD) comprising:sensing and logic circuits to sense a tachyarrhythmia through one or more sensing and shocking electrodes adapted to be coupled to a patient's heart; low and high voltage output capacitors coupled to the sensing and shocking electrodes, respectively, through an output switch; a charging circuit that charges the output capacitors to a specified energy; and a control circuit that generates control signals, the control signals being coupled to the charging circuit and output switch for controlling the charging of the low and high voltage output capacitors and the closure of the output switch in accordance with a prescribed tiered therapy, the tiered therapy including a therapy phase during which a less aggressive therapy is applied through at least one of the sensing or shocking electrodes, followed by a verification phase to determine if the less aggressive therapy was successful in terminating a sensed tachyarrhythmia, followed by a more aggressive therapy applied through at least one of the sensing or shocking electrodes in the event the less aggressive therapy was not successful in terminating the sensed tachyarrhythmia; the control circuit further including reduced time-to-therapy means for charging the high voltage output capacitors to a prescribed energy at the same time as a specified one of the therapy phase or the verification phase is being carried out in accordance with the prescribed tiered therapy;whereby the ICD automatically uses the least aggressive therapy of the prescribed tiered therapy as it attempts to terminate tachyarrhythmias, and in doing so employs an early charging feature to reduce the time to therapy. 10. The implantable ICD, as set forth in claim 9, wherein the reduced time-to-therapy means charges the high voltage output capacitors to the prescribed energy at the same time as the therapy phase of a prior less aggressive therapy.
11. The implantable ICD, as set forth in claim 9, wherein the reduced time-to-therapy means charges the high voltage output capacitors to the prescribed energy at the same time as the verification phase of a prior less aggressive therapy.
12. The implantable ICD, as set forth in claim 11, wherein the prescribed tiered therapy includes three different therapies, a first therapy comprising the application of low energy stimulation pulses, a second therapy comprising the application of a moderate energy stimulation pulse, and a third therapy comprising the application of a high energy stimulation pulse; the first therapy being a less aggressive therapy than either the second or third therapy; the second therapy being a less aggressive therapy than the third therapy, but a more aggressive therapy than the first therapy; and the third therapy being a more aggressive therapy than either the first or second therapy.
13. The implantable ICD, as set forth in claim 12, wherein the specified energy to which the output capacitors are charged in accordance with the second therapy comprises 1 to 10 joules.
14. The implantable ICD, as set forth in claim 12, wherein the specified energy to which the output capacitors are charged in accordance with the third therapy comprises 11 to 40 joules.
15. The implantable ICD, as set forth in claim 12, wherein the low energy stimulation pulses are applied in a prescribed sequence that includes a selected one of ramp pacing, burst pacing, or scanning pacing.
16. The implantable ICD, as set forth in claim 12, wherein the low voltage output capacitors are used in providing the first therapy, and the high voltage output capacitors are used in providing the second and third therapies.
17. The implantable ICD, as set forth in claim 9, wherein the charging circuit includes:a transformer that couples a primary power source to the high voltage output capacitor as controlled by control signals generated by the control circuit, the control signals creating an ON time during which a primary winding of the transformer is connected to the primary power source, and an OFF time during which the primary winding is disconnected from the primary power source; and current sensing means for sensing the charging current flowing through the transformer and for controlling the duration of the ON and OFF times as a function of the charging current thus sensed. 18. The implantable ICD, as set forth in claim 17, wherein the current sensing means senses when the charging current during the ON time reaches a prescribed peak value, and wherein the control circuit terminates the ON time as soon as the charging current reaches the prescribed peak value, the prescribed peak value being selected so as to charge the high voltage output capacitor to the specified energy in prescribed increments.
19. The implantable ICD, as set forth in claim 18, wherein the current sensing means senses when the charging current during the OFF time has decayed to a prescribed minimum value, and wherein the control circuit terminates the OFF time as soon as the charging current reaches the prescribed minimum value; whereby the duration of the OFF time is minimized.
20. The implantable ICD, as set forth in claim 19, wherein the prescribed minimum value is zero.
21. A method of operating an implantable cardioverter-defibrillator (ICD), the ICD having output means for delivering an electrical shock of a prescribed energy to the heart of a patient, and means for sensing a tachyarrhythmia of the patient's heart; the method comprising the steps of:(a) sensing a tachyarrhythmia; (b) issuing a first therapy comprising an electrical shock of a first energy in an attempt to terminate the sensed tachyarrhythmia; (c) checking to see if the first therapy was successful in terminating the tachyarrhythmia; (d) charging a high voltage output capacitor of the ICD to a specified charge level in anticipation of applying a second therapy comprising an electrical shock of a second energy, the second energy being greater than the first energy, the charging of the high voltage output capacitor for application of the second therapy being commenced simultaneously with the checking of step (c); and (e) issuing the second therapy as soon as the charging of step (d) has been completed, and as soon as a determination has been made in step (c) that the first therapy was not successful. 22. The method, as set forth in claim 21, further including:(f) checking to see if the second therapy was successful in terminating the tachyarrhythmia; (g) charging the high voltage output capacitor of the ICD to a different specified charge level in anticipation of applying a third therapy comprising an electrical shock of a third energy, the third energy being greater than the second energy, the charging of the high voltage output capacitor for application of the third therapy being commenced simultaneously with the checking of step (f); and (h) issuing the third therapy as soon as the charging of step (g) has been completed, and as soon as a determination has been made in step (f) that the second therapy was not successful. 23. The method, as set forth in claim 22, wherein the second energy comprises 5 to 10 joules, and the third energy comprises 11 to 40 joules.
24. The method, as set forth in claim 21, further including repeating steps (b) to (d) a prescribed number of times before commencing step (e).
25. The method, as set forth in claim 24, wherein the prescribed number of times that steps (b) to (d) are repeated before commencing step (e) comprises at least two times.
The present invention relates to implantable medical devices and methods, and more particularly, to an implantable cardioverter-defibrillator (ICD) having an early charging capability. Such capability reduces the time it takes to receive a higher energy shock of a tiered shock therapy when a heart has not responded to a lower energy shock.
It is known in the ICD art to provide a "tiered" therapy with regard to the termination of sensed tachyarrhythmias. The term "tiered" therapy has been used typically to describe the different tachyarrhythmia rate zones, such as low rate ventricular tachycardia (VT Low), high rate tachycardia (VT High), and ventricular fibrillation (VF). The term "tiered therapy" also has been used to describe the increasing degree of aggressiveness within each rate zone. For example, within each zone the physician may program the number of stimulation pulses, the interval between stimulation pulses, the energy level of the stimulation, and the number of attempts, etc. Thus, based upon the detected rate of the arrhythmia, the ICD will continue to increase the level of aggressiveness until such arrhythmia is terminated.
For example, upon sensing a low rate ventricular tachycardia, an ICD may attempt to terminate such tachycardia by first applying a prescribed type of antitachycardia ("antitach") pacing. Such antitach pacing typically includes burst pacing, ramp pacing, and/or scanning pacing, as is known in the art. See, e.g., U.S. Pat. Nos. 4,427,011 and 4,541,430 (burst pacing); 4,398,536 (ramp pacing); and 5,103,822 (scanning pacing); which patents are incorporated herein by reference. If the antitach pacing is unsuccessful, the ICD may be programmed to apply a low energy, cardioversion energy shock in an attempt to cardiovert the heart. If the low energy cardioversion shock is unsuccessful, the ICD may apply a higher energy shock in an attempt to cardiovert the heart. If the tachycardia accelerates to ventricular fibrillation, the system will then apply a high energy defibrillation shock with starting values typically on the order of 10 joules and increasing up to 40 joules.
It should be noted that the basic difference between cardioversion and defibrillation is the type of arrhythmia being detected. That is, the term "cardiovert" or "cardioversion" refers to the application of energy shock treatment to a heart in response to a sensed ventricular tachycardia in an attempt to terminate the tachycardia. The term "defibrillate" or "defibrillation," on the other hand, refers to the application of energy shock treatment to a heart in response to a sensed ventricular fibrillation in an attempt to terminate the fibrillation. Cardioversion is often thought of as being "low energy" since the heart has been known to successfully convert the arrhythmia with electrical shocks in the range of 0.1 to 10 joules. However, it is still classified as cardioversion if the arrhythmia is a ventricular tachycardia even if the energy required to convert the arrhythmia goes up to the maximum value (e.g., 40 joules). Defibrillation, on the other hand, is often thought of as being "high energy" since the heart has been successfully defibrillated with energy shocks in the range of 10 to 40 joules. In contrast, the pacing pulses that are applied to a heart during normal or antitach pacing are typically of much lower energy (e.g., between 50 and 200 micro joules). The principal difference between the types of therapy provided by an ICD supporting tiered therapy is that of arrhythmia detection and the programmed level of aggressiveness with the therapy typically starting by applying the lowest energy stimulation for that detected arrhythmia and working its way up to high energy shock therapy, as required.
The energy shock, whether cardioversion or defibrillation, is delivered to the heart via what is commonly referred to as "defib leads," "defibrillation lead or electrode," or "patch electrodes." However, it is recognized that the electrode system could also be epicardial electrodes (attached to the external surface of the heart) or endocardial (attached to the internal surface of the heart) or any combination of patch, epicardial or endocardial. Such electrodes are well known in the art. See, for example, U.S. Pat. No. 4,662,377 (Heilman et al.), issued May 5, 1987, entitled "Cardioverting Method and Apparatus Utilizing Catheters and Patch Electrodes"; U.S. Pat. No. 4,481,953 (Gold et al.), issued Nov. 13, 1984, entitled "Endocardial Lead Having Helically Wound Ribbon Electrode"; and U.S. Pat. No. 4,010,758 (Rockland et al.), issued Mar. 8, 1977, entitled "Bipolar Body Tissue Electrode," which patents are hereby incorporated herein by reference. Hereinafter, the electrodes (whether patch, epicardial, or endocardial, etc.) will be referred to as simply "shocking electrodes."
In order to apply an electrical pulse to the heart (whether of low, moderate or high energy), it is first necessary to charge one or more output capacitors of the ICD device with an electrical charge of the desired energy. Typically, one set of low voltage output capacitors (which may be a single capacitor) is charged to provide the requisite energy for normal or antitach pacing. The normal pacing lead(s) is then A.C. coupled to such set of low voltage capacitors through an appropriate output switch. Another set of capacitors, which is generally a set of high voltage capacitors, is charged to provide the requisite energy for cardioversion or defibrillation. Appropriate shocking electrodes are then coupled to such set of high voltage capacitors through an appropriate high voltage output switch. When an electrical stimulation pulse is to be applied to the heart, the appropriate output switch is closed to connect the low or high voltage output capacitor(s) to the cardiac tissue through either the pacing or shocking electrodes, thereby effectively "dumping" the charge stored in the low or high voltage output capacitor(s) across the cardiac tissue.
All tiered therapy ICD's known to applicants begin to charge their output capacitor(s) following verification of the failure of the previous less aggressive therapy. For example, as soon as the ICD sensing and logic circuits determine that the first tier of therapy (e.g., antitach therapy) has not successfully terminated the tachyarrhythmia, the high voltage output capacitors are charged to the appropriate energy for a second tier of therapy (e.g., cardioversion in the case of ventricular tachycardia; or defibrillation in the case of ventricular fibrillation). As soon as the ICD sensing and logic circuits determine that the second tier of therapy has not successfully terminated the tachyarrhythmia, the high voltage output capacitors are charged to a higher energy level. Unfortunately, it may take 3-4 seconds to charge the high voltage output capacitors to a moderate energy level to (1 to 10 joules), and 7-15 seconds to charge such capacitors to a high energy level (11 to 40). Disadvantageously, these charging times represent a significant period of time, or "time-to-therapy," during which the tachyarrhythmia continues without the benefit of having the ICD apply any therapy. Furthermore, as the duration of the tachyarrhythmia lengthens, it becomes increasingly more difficult to terminate the arrhythmia with an electrical stimulus. Thus, what is needed is an ICD device wherein the time-to-therapy is reduced, thereby reducing the exposure of the patient to the tachyarrhythmia, and thereby increasing the probability of success of the cardioversion-defibrillation attempt.
The present invention addresses the above and other needs by providing an implantable cardioverter-defibrillator (ICD) that automatically uses the least aggressive therapy of a tiered therapy as it attempts to terminate tachyarrhythmias, and in so doing, employs an early charging feature to reduce the "time-to-therapy." The ICD of the invention includes sensing and logic circuits to sense a tachyarrhythmia through one or more sensing and/or shocking electrodes. The ICD also includes low and high voltage output capacitors that store an appropriate energy suitable for a selected therapy. A charging circuit charges the output capacitors to the appropriate energy, and an output switch selectively connects the output capacitors to the appropriate pacing or shocking electrodes. The operation of the ICD is controlled by a control circuit. The control circuit controls, among other things, when the low or high voltage output capacitors are charged, the energy level to which such capacitors are charged, and when the output switch connects such capacitors to cardiac tissue through the pacing or shocking electrodes.
Like ICD's of the prior art, the present invention begins with a less aggressive (lower energy) therapy according to the sensed tachyarrhythmia and increases aggressiveness accordingly. For example, in the presence of a tachycardia, the ICD of the present invention may first apply antitachycardia pacing (a prescribed burst or sequence of low energy pacing pulses), if so programmed, in an attempt to terminate the sensed tachycardia. If the tachycardia persists, the ICD may advance to a cardioversion (initially, a low energy shock with increasing energy shocks until terminated). Whenever the ICD detects ventricular fibrillation, the ICD will apply a defibrillation pulse (a high energy shock).
Unlike ICD's of the prior art, however, the control circuit of the ICD of the present invention causes the high voltage output capacitors of the ICD (used to store the energy that is applied during cardioversion or defibrillation) to begin charging during the application of the less aggressive therapy, or during the interval immediately following a prior therapy attempt during which the ICD sensing and logic circuits attempt to verify the successful termination of the tachyarrhythmia. In this manner, the needed cardioversion or defibrillation therapy may be applied immediately following confirmation of the failure of a less aggressive (lower energy) therapy, without having to wait while the high voltage output capacitors are charged. Hence, the time-to-therapy is significantly reduced, advantageously increasing the probability of success of the cardioversion-defibrillation attempt and reducing the exposure of the patient to the tachyarrhythmia.
An ICD made in accordance with the present invention may thus be characterized as including a sensing circuit that senses electrogram (EGM) signals through a sensing lead coupled to a patient's heart; control logic and timing circuits that determine whether the EGM signals sensed by the sensing circuit are indicative of a tachyarrhythmia; and a pulse generator that selectively generates stimulation pulses of a first energy in a prescribed pattern as controlled by the control logic and timing circuits. The stimulation pulse of the first energy is applied to the patient's heart through the sensing lead in an attempt to terminate the sensed tachyarrhythmia. The ICD also includes at least one shocking electrode coupled to the patient's heart; and a cardioversion-defibrillation circuit that selectively generates stimulation pulses of a second energy as controlled by the control logic and timing circuits. The stimulation pulses of the second energy are applied to the patient's heart through the shocking electrode(s) in a further attempt to terminate the sensed tachyarrhythmia. That is, the control logic and timing circuits are configured to terminate the sensed tachyarrhythmia in accordance with a tiered therapy (i.e., with increasing aggressiveness according to the detected arrhythmia).
The tiered therapy includes a first tier (e.g., antitach pacing) that applies the stimulation pulses of the first energy (e.g., a level safely above stimulation threshold) in response to sensing a given tachycardia, and a second tier (e.g., cardioversion) that applies the stimulation pulses of the second energy (e.g., low or moderate amplitude cardioversion shocks) immediately after determining that the first tier could not successfully terminate the tachycardia. In this manner, in the event the first tiered therapy does not terminate the tachycardia, the second tier of therapy is immediately applied.
In accordance with one aspect of the above-characterized invention, the cardioversion-defibrillation circuit further selectively generates stimulation pulses of a third energy (e.g., higher amplitude shocks) as controlled by the control logic and timing circuits. The stimulation pulses of the third energy are also applied to the patient's heart through the shocking electrode(s). Thus, the tiered therapy further includes a third tier (e.g., high energy shock cardioversion or defibrillation) that applies the stimulation pulses of the third energy as soon as possible after determining that the sensed tachyarrhythmia was not terminated by the second tier.
The invention, in accordance with another aspect thereof, may be characterized as an ICD having (a) sensing and logic circuits to sense a tachyarrhythmia through one or more sensing and shocking electrodes coupled to a patient's heart; (b) low and high voltage output capacitors coupled to the sensing and shocking electrodes, respectively, through an output switch; (c) a charging circuit that charges the output capacitors to a specified energy; and (d) a control circuit that generates control signals. In operation, the control signals are coupled to the charging circuit and output switch for the purpose of controlling the charging of the low and high voltage output capacitors, as well as the closure of the output switch, in accordance with a prescribed tiered therapy. The tiered therapy includes a therapy phase during which a less aggressive therapy is applied through at least one of the sensing or shocking electrodes, followed by a verification phase during which a determination is made if the less aggressive therapy was successful in terminating a sensed tachyarrhythmia. If not successful, the verification phase is followed immediately by a more aggressive therapy applied through at least one of the sensing or shocking electrodes. Advantageously, the control circuit of the ICD further includes reduced time-to-therapy means for charging the high voltage output capacitors to a prescribed energy at the same time as a specified one of the therapy phase or the verification phase is being carried out in accordance with the prescribed tiered therapy. Thus, the ICD automatically uses the least aggressive therapy of the prescribed tiered therapy as it attempts to terminate tachyarrhythmias, and in doing so, advantageously employs an early charging feature to reduce the time-to-therapy.
The present invention may further be characterized as a method of operating an ICD, where the ICD has output means for delivering an electrical shock of a prescribed energy to the heart of a patient and means for sensing a tachyarrhythmia of the patient's heart. Such method comprises the steps of: (a) sensing a tachyarrhythmia; (b) issuing a first therapy comprising an electrical shock of a first energy in an attempt to terminate the sensed tachyarrhythmia; (c) checking to see if the first therapy was successful in terminating the tachyarrhythmia; (d) charging a high voltage output capacitor of the ICD to a specified charge level in anticipation of applying a second therapy comprising an electrical shock of a second energy, the second energy being greater than the first energy, the charging of the high voltage output capacitor for application of the second therapy being commenced simultaneously with the checking of step (c); and (e) issuing the second therapy as soon as the charging of step (d) has been completed, and as soon as a determination has been made in step (c) that the first therapy was not successful.
The method summarized above may be extended, as required, to include the additional steps of: (f) checking to see if the second therapy was successful in terminating the tachyarrhythmia; (g) charging the high voltage output capacitor of the ICD to a different specified charge level in anticipation of applying a third therapy comprising an electrical shock of a third energy; and (h) issuing the third therapy as soon as the charging of step (g) has been completed, and as soon as a determination has been made in step (f) that the second therapy was not successful. In carrying out this method, the third energy is greater than the second energy, and the charging of the high voltage output capacitor for application of the third therapy is commenced simultaneously with the checking of step (f).
It is thus a feature of the invention to provide a tiered-therapy ICD that affords a reduced time-to-therapy, thereby reducing the exposure of the patient to a tachyarrhythmia, and thereby increasing the probability of a successful cardioversion-defibrillation attempt.
It is a further feature of the invention to begin charging the high voltage output capacitors of a tiered-therapy ICD during the application of a less aggressive therapy, or while the ICD is attempting to verify if a prior therapy attempt was successful, thereby allowing such capacitors to be fully charged and ready in the event a more aggressive therapy is needed.
It is another feature of the invention to provide a charging circuit for charging one or more high voltage output capacitors within a tiered-therapy ICD device that minimizes the time period required to obtain a prescribed charge on the high voltage output capacitors.
The above and other aspects, features and advantages of the present invention will be more apparent from the following descriptions of the drawings:
FIG. 1 shows a simplified functional block diagram of an implantable cardioverter-defibrillator (ICD) capable of providing a tiered therapy output;
FIG. 2 is a timing diagram that diagrammatically illustrates the type of tiered output provided by the ICD of FIG. 1 when operated in accordance with the teachings of the prior art;
FIG. 3 is a timing diagram as in FIG. 2 that diagrammatically illustrates the tiered output of an ICD when operated in accordance with the teachings of the present invention, and illustrates how the time-to-therapy is reduced;
FIGS. 4-1 and 4-2 show a flow diagram that illustrates the operation of the ICD of FIG. 1 in order to provide a reduced time-to-therapy in accordance with the present invention;
FIG. shows a simplified electrical schematic diagram of the rapid high voltage charging circuit used by the ICD of FIG. 1; and
FIG. 6 depicts a timing waveform diagram that illustrates the basic operation of the rapid charging circuit of FIG. 5.
Typically, a tachyarrhythmia is a rapid irregular rhythm of the heart, e.g., ventricular tachycardia or ventricular fibrillation. However, for purposes of the present invention a tachyarrhythmia may also include atrial tachycardia, atrial fibrillation, as well as asystole (a stopped heart). As used hereinafter, the term "tachyarrhythmia" is used broadly to indicate any irregular rhythm of the heart that interferes with the heart's ability to perform its basic function of a pump and requires intervention by an ICD.
It is the primary function of an implantable cardioverter-defibrillator (ICD) device to sense the occurrence of a tachyarrhythmia, and to automatically apply an appropriate therapy to the heart aimed at terminating the tachyarrhythmia. To this end, an ICD device 20 made in accordance with the present invention includes, as shown in the functional block diagram of FIG. 1, control logic and timing circuits ("control/timing" circuits) 22 that control a pulse generator 24 and a high voltage generator 26. The pulse generator 24 generates output stimulation pulses of low energy (antitach pulses), e.g., electrical pulses having an energy of less than 200 micro joules, as controlled by the control/timing circuit 22 and an antitach pacing circuit 23. Such antitach pulses are applied to a patient's heart 28 through a conventional pacing lead 30 having an electrode 32 in contact with the cardiac tissue (usually inside the right ventricle and/or right atrium). While only a single pulse generator 24 and pacing lead 30 are shown in FIG. 1, it is to be understood that the invention is not so limited and may, for example, include a second pulse generator and pacing lead, as is known in the art, to deliver dual-chamber pacing or antitach pulses to a patient's heart.
The high voltage generator 26 generates output electrical stimulation pulses of moderate (e.g., 1 to 10 joules) or high energy (e.g., 11 to 40 joules), as controlled by the control/timing circuit 22. Such energy pulses are applied to the patient's heart through at least two shocking electrodes 34 and 36, each of which is respectively coupled to a suitable shocking electrode 38 and 40. Typically, the shocking electrodes 38 and 40 are patch electrodes that are placed in contact with, or near, external cardiac tissue. The shocking electrodes 38 and 40 may be of conventional design and may be implanted using known techniques, as shown, e.g., in U.S. Pat. Nos. 4,774,952 (Smits); 4,991,603 (Cohen et al.) and 4,998,975 (Cohen et al.), incorporated herein by reference. While only two shocking electrodes and electrodes are shown in FIG. 1, it is to be understood that additional shocking electrodes may be used as desired or needed in order to efficiently and effectively apply the shock treatment generated by the high voltage generator 26 to the patient's heart 28.
The ICD 20 also includes a sense amplifier 42 that is coupled to the pacing lead 30 and electrode 32. It is the function of the sense amplifier 42 to sense the activity of the heart 28 as manifest by the presence of certain electrical signals picked up by the electrode 32. That is, as is known in the art, R-waves occur upon the depolarization, and hence contraction, of ventricular tissue; and P-waves occur upon the depolarization, and hence contraction, of atrial tissue. Thus by sensing R-waves through the sense amplifier 42 and providing such sensed signals to the control/timing circuit 22, the control/timing circuit 22 is able to make a determination as to the rate and regularity of the patient's heartbeat. Such information, in turn, allows the control/timing circuit 22 to determine whether the heart 28 is experiencing a tachyarrhythmia. (Similarly, in a dual-chamber pacing device, P-waves could be sensed by a sense amplifier (not shown) to enable the control/timing circuit 22 to make a determination as to any atrial arrhythmia.)
The control/timing circuit 22 further has a memory circuit 44 coupled thereto wherein the operating parameters used by the control/timing circuit 22 are stored. Such operating parameters may define, for example, the amplitude of the antitach and high voltage stimulation pulses that are to be generated, the type of pattern (e.g., burst, scan and/or ramp) of antitach pulses that are to be used, the timing intervals used to determine whether a tachyarrhythmia is present, and the like. Advantageously, such operating parameters may be noninvasively programmed into the memory 44 through a telemetry circuit 46 that is in telecommunicative contact with an external programmer 48 by way of a suitable coupling coil 50. The coupling coil 50 may serve as an antenna for establishing a radio frequency (RF) communication link 52 with the external programmer 48; or the coil 50 may serve as a means for inductively coupling data to and from the telemetry circuit 46 from and to the external programmer 48. Further, such telemetry circuit 46 advantageously allows status information relating to the operation the ICD 20, as contained in the control/timing circuit 22 or memory 44, to be sent to the external programmer 48 through the established link 52.
The design, operation and use of the telemetry circuit 46 and external programmer 48 to selectively program operating parameters into the memory 44, or to selectively monitor the operating status of the ICD 20, may be the same as are known in the pacing art. See, e.g., U.S. Pat. Nos. 4,809,697 (Causey, III et al.) and 4,944,299 (Silvian), incorporated herein by reference.
The control/timing circuit 22 includes appropriate logic circuits for analyzing the output of the sense amplifier 42 and determining if such signals indicate the presence of a tachyarrhythmia. Typically, such determination is made by determining the rate of the sensed R-waves and/or P-waves and comparing the determined rate against: (1) a low tachycardia reference rate; (2) a high tachycardia reference rate; (3) a maximum (fibrillation) reference rate; or (4) a minimum threshold reference rate (to determine if asystole, or a stopped heart, is present). If a tachyarrhythmia is sensed, then appropriate circuits included in the control/timing circuit 22 are triggered to apply a prescribed tiered therapy.
The prescribed tiered therapy may advantageously be programmed into the memory 44. A preferred tiered therapy is described below in conjunction with FIGS. 4-1 and 4-2. Basically, such tiered therapy is implemented by generating, in a controlled time sequence, a series of control signals that activate various elements or features of the invention. For example, a first control signal, appearing on signal line 25, enables the antitach pacing circuit 23. A second control signal, appearing on signal line 27, triggers the pulse generator 24 to deliver the antitach pacing defined by the antitach pacing circuit 23 at a controlled time within the cardiac cycle. (The "cardiac cycle" is the time for one complete heartbeat, and includes the depolarization of the atrium and the depolarization of the ventricle.) The antitach pacing circuit 23 defines a selected type of antitach pacing (e.g., burst pacing, ramp pacing, or scan pacing) that is delivered to the heart at the time controlled by the antitach pacing control signal 27.
Similar control signals generated by the control/timing circuit 22 control the operation of the high voltage generator 26. As seen in FIG. the high voltage generator 26 includes a rapid charge circuit 54, one or more output capacitors 56, and an output switching network 58. When the control/timing circuits 22 determine the need for a moderate or high energy output pulse, an enable signal 60 enables the rapid charge circuit 54 so that it begins to charge the output capacitor 56 using power derived from a battery 62. As the output capacitor 56 is thus charged, it is monitored via signal line 64 to determine if the charge (voltage) stored thereon is at a prescribed level. The prescribed level is defined by an appropriate charge level signal that may be programmably stored in the memory 44. Once the prescribed charge level has been reached, which may take several seconds depending upon the charge level desired, the output capacitor 56 thereafter stands ready to discharge the energy stored thereon through the output switching network 58 to the heart 28. Thus, another control signal 66 controls the output switching network 66 so as to cause the high energy stimulus stored on the output capacitor 56 to be delivered at a prescribed time.
The control/timing circuits 22, as well as the antitach circuit 23, may be implemented using conventional logic circuitry, i.e., registers and logic gates, preferably configured in a suitable state machine. The use of state machine logic circuitry to control an implantable medical device is described, e.g., as shown in U.S. Pat. No. 4,712,555 (Thornander et al.), incorporated herein by reference.
Alternatively, the control/timing circuit 22, antitach pacing circuit 23, and memory circuitry 44 may be implemented using a suitable microprocessor 68. In such instance, an operating program is stored in the memory 44 to control the operation of the processor. Typically, such operating program is permanently stored in read only memory (ROM) included as part of the memory 44 of the microprocessor 68, while certain operating parameters or variables associated with the operating program may be downloaded from the external programmer 48 to random access memory (RAM), also included as part of the memory 44. The use of a microprocessor to control an implanted medical device is described, e.g., in U.S. Pat. No. 4,940,052 (Mann et al.), incorporated herein by reference.
The pulse generator 24 of FIG. 1 may be of conventional design, such as is disclosed in U.S. Pat. No. 4,739,437 (Morgan), incorporated herein by reference. Basically, the pulse generator 22 includes an output pulse capacitor (not shown) on which a specified charge (voltage) is stored. Typically, because the charge (voltage) stored on such output pulse capacitor must be greater than the voltage available from the battery 62 included with the implantable device, a charging circuit is employed as part of the pulse generator 24 to "pump" up the voltage from the existing battery 54 to a specified voltage that is stored on the output pulse capacitor. When the stimulation pulse is to be generated by the pulse generator, an output switch is closed. The output switch connects the output pulse capacitor to the implantable lead, thereby "dumping" the charge held on the capacitor through the lead 30 and electrode 32 to desired cardiac tissue.
Those having experience in the cardioversion and defibrillation art will readily recognize that the ICD 20 shown in FIG. 1 is structurally very similar to prior art ICD's. That is, ICD's of the prior art include both a pulse generator and a high voltage output circuit for delivering a tiered therapy to cardiac tissue as controlled by an appropriate control/timing circuit. The principal difference between the ICD 20 of the present invention and prior art ICD's lies primarily in how the ICD operates, e.g., as controlled by the control/timing circuit 22, and in how the rapid charge circuit 54 is configured to charge the output capacitor 56 in a more rapid manner than has previously been achieved.
To better understand the operation of the ICD 20 shown in FIG. 1, and the differences between such operation and the operation of a prior art ICD, reference is next made to FIGS. 2 and 3. FIG. 2 is a timing diagram that diagrammatically illustrates the type of tiered output provided by a prior art ICD in response to a sensed tachycardia, which prior art approach may be characterized as a serial approach. As seen in FIG. 2, at time t1, a tachycardia is sensed. The ICD responds by applying a first tiered therapy, (e.g., antitach pacing) comprising three bursts 80 of stimulation pulses. A fixed time tD after the last burst 80 of pulses (which fixed time tD represents the tissue refractory time periods that follow application of any stimulation pulse), the results of the antitach pacing are checked to determine if the first tiered therapy successfully terminated the sensed tachycardia. Such checking, or verification, is performed by the sensing circuits 42 in combination with the control/timing circuits 22 (or, if used, the microprocessor 68), and is represented in FIG. 2 by the box 82, labeled CHECK RESULTS.
The verification, or checking, performed after the conclusion of the antitach pacing takes a finite time period, represented in FIG. 2 by the length of the box 82. If, as a result of such checking 82, a determination is made that the antitach pacing was not successful in terminating the tachycardia, then, in anticipation of applying a second tiered therapy, the output capacitor is charged to a level suitable for delivery of a moderate energy level (e.g., 0.1 to 10 joules) cardioversion pulse. Such charging begins at time t2 and is not completed until time t3. As soon as the output capacitor is charged to the specified level for a cardioversion pulse, i.e., at time t3, a cardioversion pulse 84 is delivered (i.e., the output capacitor is discharged across the cardiac tissue, resulting in the cardioversion pulse 84).
Following delivery of the cardioversion pulse 84 and an associated delay tD, the results of the application of the cardioversion pulse 84 are checked, represented by the CHECK RESULTS box 86. If, as a result of such checking 86, a determination is made that the cardioversion pulse was not successful in terminating the tachycardia or if the tachycardia accelerated into ventricular fibrillation, then, in anticipation of applying a third tiered therapy, the output capacitor is charged to a higher energy level pulse. Such charging begins at time t4 and is not completed until time t5. As soon as the output capacitor is charged to the specified level, i.e., at time t5, a higher energy level pulse 88 is delivered (i.e., the output capacitor is discharged across the cardiac tissue, resulting in the higher energy level pulse 88).
Thus, it is seen in FIG. 2 that the prior art serial approach is to apply a first tiered therapy (e.g., antitach pacing with burst pacing) and check to see if it was successful. If not, the output capacitor is charged in anticipation of applying a second tiered therapy (e.g., cardioversion pulse). As soon as the output capacitor is charged, the second tiered therapy (e.g., a low or moderate energy level cardioversion pulse) is applied, and the results are checked to see if successful. If not, the output capacitor is again charged in anticipation of applying a third tiered therapy (e.g., a high energy pulse). As soon as the output capacitor is charged sufficiently to deliver the high energy level pulse, the third tiered therapy is finally applied. Unfortunately, due to the relatively long time that it takes to charge the output capacitor sufficient for delivery of a cardioversion or defibrillation pulse, the time-to-therapy is correspondingly long. Because of this long time-to-therapy, the therapy that is eventually applied may not be as successful as it might have been if it could have been applied sooner.
In contrast to the serial approach of applying a tiered therapy shown in FIG. 2, the present invention utilizes a parallel tiered therapy approach as shown in FIG. 3. Advantageously, using the approach shown in FIG. 3, the time-to-therapy is significantly reduced, even through the individual events that must occur (e.g., certain refractory delays tD, and capacitor charge times) are generally the same.
Referring to FIG. 3, it is seen that a tachycardia is sensed at time t1, and the first tiered therapy (e.g., antitach pacing, as represented by the application of three bursts 80 of stimulation pulses) is applied in response thereto, just as in the prior art approach shown in FIG. 2. Unlike the prior art approach, however, the present invention begins to charge the output capacitor 56 in anticipation of delivering the second tiered therapy (e.g., a low or moderate energy level cardioversion pulse) at time t6, which is in parallel with the commencement of the first tiered therapy. Thus, while the first tiered therapy is being applied, the output capacitor(s) is being charged in anticipation of applying the second tiered therapy. Hence, at the completion of the first tiered therapy, and after the requisite refractory delay tD, and as soon as a verification can be made that the first tiered therapy was not successful in terminating the tachyarrhythmia (i.e., at the conclusion of the CHECK RESULTS event 82 at time t8), the second tiered therapy (application of the cardioversion pulse 84) can be immediately applied.
Still referring to FIG. 3, it is seen that soon after the cardioversion pulse 84 has been applied (i.e., beginning at time t9), the output capacitor is again charged in anticipation of applying the third tiered therapy (e.g., a high energy level cardioversion or defibrillation pulse). Thus, while the output capacitor is being charged, the results of the second tiered therapy may be checked, as represented by the CHECK RESULTS event 86, at the conclusion of the delay tD. Hence, the verification of the second tiered therapy proceeds simultaneously with the charging of the output capacitor. As a result, as soon as the output capacitor is charged, at time t10, the third tiered therapy--application of the high energy pulse 88--may immediately occur.
Note that as illustrated in FIG. 3, the charging of the output capacitor in anticipation of delivering the second tiered therapy (i.e., the low to moderate energy level cardioversion pulse) is completed at a time t7 which is prior to the completion of the application of the first tiered therapy and its verification. Hence, it is the completion of the verification of the first tiered therapy (the end of CHECK RESULTS 82) that limits the time when the second tiered therapy may be applied. However, in some applications, it may be desirable to begin the charging of the output capacitor during the verification of the first tiered therapy, (i.e., at the beginning of the CHECK RESULTS 82) in order to reduce the drain on the battery, or for other reasons. In such event, the charging of the output capacitor may not be completed prior to the completion of the verification of the first tiered therapy, and the second tiered therapy will thus not be able to be applied until the output capacitor has been charged. In other words, whichever of the two parallel events or sequences (the charging of the output capacitor or the verification of the prior tiered therapy) concludes last determines when the next tiered therapy may be applied.
The above discussion also applies to the charging of the output capacitor in anticipation of delivering the third tiered therapy. That is, it is the longest of two parallel events or sequences--the charging of the output capacitor or the verification of the second tiered therapy--that limits when the third tiered therapy may be applied. As suggested by the timing diagram of FIG. 3, the charging of the output capacitor in anticipation of delivering the high energy pulse 88 may be significantly longer than verifying whether the second tiered therapy was successful in terminating the tachyarrhythmia. However, such may not always be the case, particularly if the CHECK RESULTS 86 involves several checks and cross-checks.
It is further noted that the tiered therapy that is applied in accordance with the present invention need not necessarily be a "single shot" therapy as suggested in FIGS. 2 and 3. That is, FIG. 3 shows that three bursts of pulses 80 are applied (first tiered therapy) and are found to be unsuccessful; so a single cardioversion pulse 84 is applied (second tiered therapy), is found to be unsuccessful; so a single high energy level pulse 88 is applied (third tiered therapy). That is, as shown in FIG. 3, each tiered therapy is applied only once. However, it is to be understood that the present invention contemplates that each tiered therapy may be applied a programmed number of times, e.g., from one to ten, before advancing to the next (more aggressive) tiered therapy.
While the embodiment illustrated in FIGS. 2 and 3 is an example of one type of response by the ICD to a tachycardia, it is but one of many possible programmable therapies available. For example, the first, second and third tiered therapies might comprise a low, moderate and high amplitude cardioversion pulse in response to the atrial or ventricular tachycardia. As another example, the first, second and third tiered therapies might comprise a low, moderate and high amplitude defibrillation pulse in response to ventricular fibrillation or asystole. It is apparent to one skilled in the art that there are numerous programmable combinations of antitach pacing, cardioversion and defibrillation regimes possible. Whatever the desired therapy is, the present invention will begin charging the output capacitor(s) in anticipation of applying the next tiered therapy in parallel with the application of the present tiered therapy.
Thus, as seen in FIG. 3, the present invention achieves a reduced time-to-therapy by allowing certain events (such as the charging of the output capacitor) to begin and proceed while other events are still taking place (e.g., while the delivery of a lower level, less aggressive therapy is taking place), and/or while the verification of the lower level therapy is occurring.
In operation, it is thus seen that the present invention applies a "therapy phase" and a "verification phase." The therapy phase comprises charging the output capacitor in anticipation of applying the particular tiered therapy and the application of such tiered therapy. The verification phase comprises checking the sensing circuits after the therapy phase has been completed to determine if the therapy phase was successful in terminating the sensed tachyarrhythmia. The present invention recognizes and takes advantage of the fact that the therapy phase and the verification phase need not necessarily proceed in series. Rather, the therapy phase for a more aggressive therapy may begin while the therapy phase or verification phase of a less aggressive phase is still proceeding.
In addition to the reduced time-to-therapy achieved by using the parallel approach shown in FIG. 3, it is significant to note that the present invention also reduces the time-to-therapy by using a rapid charge circuit 54 that is able to place a given charge on the output capacitor 56 in a shorter time than has heretofore been achievable. Such rapid charge circuit 54 is described more fully below in conjunction with the explanation of FIGS. 5 and 6.
Referring next to FIGS. 4-1 and 4-2, there is shown a flow diagram that illustrates the operation of the ICD of FIG. 1 in order to provide a reduced time-to-therapy in accordance with the present invention. FIGS. 4-1 and 4-2 should be considered as the same figure, with portions thereof being shown on one drawing sheet, and other portions thereof being shown on another drawing sheet. Each main step of the operation shown in FIGS. 4-1 and 4-2 is represented as a block or box, having a corresponding reference numeral. Rectangular-shaped boxes or blocks represent a process or event or series of events that occur, and diamond-shaped (or hexagonal-shaped) boxes or blocks represent a determination or decision that is made that may have at least two outcomes, e.g., YES or NO. Circles and pentagonal-shaped boxes are simply connections from one location to another, with circles representing connections on the same drawing sheet, and pentagonal-shaped boxes representing connections between drawing sheets. Oval-shaped blocks or boxes signify the start or end of the reduced timed to therapy operation.
As depicted in FIG. 4-1, after the reduced time-to-therapy operation is started (block 102), the ICD is initialized (block 104). Such initialization involves retrieving all the requisite operating parameters from the memory 44, or equivalent storage device, or otherwise setting all the necessary operating parameters needed to carry out the operation. Such operating parameters define, for example, the type of the antitach pacing to be applied; the energy of the stimulation pulses to be used in antitach pacing; the number of times antitach pacing is to be applied as a first tier in the tiered therapy before stepping up to the next tier in the tiered therapy; the energy of the cardioversion pulses; the number of cardioversion pulses to be applied as a second tier in the tiered therapy before stepping up to the last tier in the tiered therapy; the energy of the defibrillation pulses to be used; and the like.
Once initialization has been completed, the normal operation of the ICD is carried out (block 106). The normal operation of the ICD, for purposes of the present invention, involves monitoring the heart activity to determine if a tachyarrhythmia is sensed (block 108). If no tachyarrhythmias are sensed, then the ICD is essentially in a "wait" state, and nothing happens until a tachyarrhythmia is sensed. [It is noted that some ICD's also include pacing capabilities, and thus provide pacing pulses on demand, as required, in order to support a basic or sensor-indicated pacing rate, just as pacemakers do. The present invention may be used with such dual-function pacers/ICD's; and if so, the normal operation, defined in block 106, includes carrying out the pacemaker operations, as are known in the art. See, e.g., U.S. Pat. No. 4,989,602 (Sholder et al.), incorporated herein by reference.]
If a tachyarrhythmia is sensed (YES branch of block 108), then a determination is made (block (109) as to whether the tachyarrhythmia is a (1) tachycardia, either fast or slow, (2) fibrillation or asystole. If it's a tachycardia, then the first tier of the tiered therapy is applied, e.g., antitach therapy (ATT) pacing (block 110).
Two events occur after applying ATT pacing (block 110). First, in anticipation of stepping up to the next level of tiered therapy, the charging of the output capacitors is initiated (block 116). Such charging continues until the output capacitor is fully charged sufficiently to deliver a cardioversion (Cardio-V) pulse (block 118). Second, a determination is made as to whether a tachyarrhythmia is still sensed (block 112). If not (NO branch of block 112), then that indicates that the ATT pacing was successful in terminating the tachyarrhythmia, and the operation of the ICD returns to its normal operation (block 106). If a tachyarrhythmia is still sensed (YES branch of block 112), then a determination is made as to whether ATT pacing should be repeated (block 114). Such determination is made based on the programmed number of times that the first tiered therapy is to be applied before stepping up to the second tiered therapy. If ATT pacing is to be repeated (YES branch of block 114), then the ICD again applies the ATT pacing (block 110). If ATT pacing is not to be repeated (NO branch of block 114), then the operation of the ICD is ready to step up to the next tier of the tiered therapy (block 120), providing that the output capacitor is fully charged (YES branch of block 118).
Thus, as soon as both the output capacitor is fully charged (blocks 116,118), and a determination is made that the first tiered therapy (ATT pacing) is not to be repeated (block 114), the operation of the ICD is ready to apply the second tier of the tiered therapy (block 120).
The second tier of the tiered therapy for the ICD being described in FIGS. 4-1 and 4-2 is the application of a cardioversion pulse (block 122). After application of the cardioversion pulse, two events occur. First, in anticipation of stepping up to the next level of tiered therapy, the charging of the output capacitors is initiated (block 126). Such charging continues until the output capacitor is fully charged sufficiently to deliver a defibrillation (defib) pulse (block 128). Second, a determination is made as to whether a tachyarrhythmia is still sensed (block 124). If not (NO branch of block 124), then that indicates that the cardioversion pulse was successful in terminating the tachyarrhythmia, and the operation of the ICD returns to its normal operation (block 106). If a tachyarrhythmia is still sensed (YES branch of block 124), then a determination is made as to whether another cardioversion pulse should be applied (block 130). Such determination is made based on the programmed number of times that the second tiered therapy is to be applied before stepping up to the third tiered therapy. If another cardioversion pulse is to be applied (YES branch of block 130), then the output capacitor(s), which may be charged for delivering a high energy pulse, are bled of any excess charge in order to reduce the charge to that required for a cardioversion pulse (block 134). Then, the cardioversion pulse is again applied (block 122). If another cardioversion pulse is not to be repeated (NO branch of block 130), then the operation of the ICD is ready to step up to the next tier of the tiered therapy (block 132), providing that the output capacitor is fully charged (YES branch of block 128)
Hence, as soon as both the output capacitor is fully charged and a determination is made at block 130 that the second tiered therapy (a cardioversion pulse) is not to be repeated, the operation of the ICD is ready to apply the third tier of the tiered therapy (block 132).
The third tier of the tiered therapy for the ICD being described in FIGS. 4-1 and 4-2 is the application of a high energy pulse for defibrillation/cardioversion (block 136, FIG. 4-2). After application of the high energy pulse, two events occur. First, in anticipation of delivering another high energy pulse, the charging of the output capacitors is again begun (block 138). Such charging continues until the output capacitor is fully charged sufficiently to deliver a high energy pulse (block 140). Second, a determination is made as to whether a tachyarrhythmia is still sensed (block 142). If not (NO branch of block 142), then that indicates that the high energy pulse was successful in terminating the tachyarrhythmia, and the operation of the ICD returns to its normal operation (block 106). If a tachyarrhythmia is still sensed (YES branch of block 142), then a determination is made as to whether another high energy pulse should be applied (block 144). Such determination is made based on the programmed number of times that the third tiered therapy is to be applied before the ICD ceases the application of the tiered therapy. If another high energy pulse is to be applied (YES branch of block 144), then a determination is made as to whether the output capacitor has been charged (block 146). If not, the ICD waits until the capacitor is charged (NO branch of block 146). If yes, then the high energy pulse is again applied (block 136).
If another high energy pulse is not to be repeated (NO branch of block 144), then the ICD records that a therapy attempt was made (block 148). For example, an appropriate flag is set in a prescribed location in the memory 44, which flag may also be time-stamped, so that a physician who subsequently examines the patient and the ICD, can readily determine that the tiered therapy was applied and the time that it was applied. Thereafter, the ICD reverts to a basic operating mode (block 150), which may be, e.g., to deliver only a single therapy in response to sensing a tachyarrhythmia, thereby terminating or ceasing operation of the ICD in accordance with a tiered therapy mode (block 152).
If however, the determination made (block 109) is fibrillation or asystole, then the first tier of the tiered therapy is the application of a defibrillation pulse (block 126 and 128). Then the second and third tier of tiered therapy would consist of progressively higher level energy shocks until the fibrillation or asystole is terminated.
It is noted that the flowcharts shown in FIGS. 4-1 and 4-2 specifically describe the tiered therapy which is illustrated in FIG. 3, in which the first tiered therapy is antitach pacing, the second tiered therapy is cardioversion and the third tier is high energy shock (either defibrillation or cardioversion). Hence, the flowcharts illustrate but one possible combination of tiered therapy. The present invention is not limited as to the type of therapy delivered and that other combinations of therapy are within the spirit of the invention.
Turning next to FIG. 5, there is shown a simplified electrical schematic diagram of the rapid high voltage charging circuit 54 used by the ICD of FIG. 1. Also shown in FIG. 5 are the output capacitors 56 and the output switching network 66. The output capacitors 56, for the configuration shown in FIG. 5, comprise two capacitors C1 and C2. The capacitors are charged through a transformer T1 as described below. The capacitor C1 is connected between a midpoint of a secondary winding of the transformer T1 and a positive high voltage bus (+HV bus). The capacitor C2 is similarly connected between the same mid point of the secondary winding of the transformer T1 and a negative high voltage bus (-HV bus). A resistor R5 and a switch S5 are shunted across the output capacitor 56 to provide a means for controlling the charge level on the capacitor 56. Such discharge resistor R5 also is used as an accurate dump resistor. That is, by closing the switch S5 for a known period of time, the value of the output capacitor 56 may be accurately determined. This is important because it allows the energy stored on the output capacitor 56 to be consistent, even through the value of the capacitor 56 may change somewhat over time. Note that the switch S5 is controlled by a control signal S5C.
Still referring to FIG. 5, it is seen that the output switching network 58 comprises an array of switches S1, S2, S3 and S4 connected between the +HV bus and the -HV bus in a classical, commonly known "H" configuration. The load, i.e., the electrodes 38 and 40 placed on the patient's heart 28 (FIG. 1), is connected as the horizontal leg of such "H" configuration. Switch S1 is placed in the left upper branch of the "H" configuration; switch S2 is placed in the right upper branch; switch S3 is placed in the lower left branch; and switch S4 is placed in the lower right branch.
When a cardioversion or defib pulse is to be applied across the heart, only two switches of the "H" configuration are closed, one from the left side and one from the right side. If switches S1 and S4 are closed, for example, the high voltage pulse is applied across the load (heart) with the lead 34 and electrode 38 being positive relative to the lead 36 and electrode 40. In contrast, if switches S2 and S3 are closed, the high voltage pulse is applied across the heart with the lead 34 and electrode 38 being negative relative to the lead 36 and electrode 40. Thus, through selective control of the switches S1, S2, S3 and S4, the polarity of the high voltage pulse applied across the heart can be changed. Note that switches S1, S2, S3 and S4 are controlled by control signals SIC, S2C, S3C and S4C, respectively.
Still referring to FIG. 5, diodes D3 and D4 are used to rectify the signal appearing at the secondary winding of the transformer T1 before such signal is applied to the output capacitor 56. A primary winding of the transformer T1 is connected between the battery voltage, VBAT, on one end, and a switch, realized with transistor Q1, in series with a current sensing resistor R1 on the other end. The switch Q1 is switched ON and OFF as controlled by the output from an oscillator circuit 160. The switched end of the transformer T1 is also coupled to ground through resistors R3 and R4, connected in series. The resistors R3 and R4 function as a voltage divider that allows the voltage developed at the primary winding to be monitored. The voltage appearing between resistors R3 and R4 is referred to as the transformer voltage VT. The voltage VT is compared with the battery voltage VBAT by a comparator circuit 166. It is the function of the comparator circuit 166 to determine when the current flowing through the primary winding of the transformer is zero, as explained more fully below in conjunction with FIG. 6.
Two diodes D1 and D2 are connected in series across the primary winding of the transformer T1 so as to clamp the voltage appearing at the switched end of the transformer to no more than two forward-biased diode voltage drops (approximately 1.4 volts) above the battery voltage, VBAT, when the transistor switch Q1 is opened.
The voltage developed across the current sense resistor R1 is a function of the transformer current, iT. This voltage is monitored through a one-pole filter 164, comprising resistor R2 and capacitor C3, and compared to a programmable reference voltage VREF by a comparator circuit 162. The output of the comparator circuit 162 is directed to the oscillator 160. It is the function of the comparator circuit 162 to determine when the transformer current iT (or more precisely the voltage developed across R1 as a result of the transformer current iT) is at a peak value as defined by the reference voltage VREF. When the transformer current reaches the specified peak value, the oscillator changes its output signal state, as explained more fully below in FIG. 6, which causes the switch Q1 to turn OFF.
The operation of the rapid charging circuit is illustrated with reference to FIG. 6, which depicts a timing waveform diagram of the output of the oscillator 160, the transformer current iT, the flyback transformer current iF, and the transformer voltage VT. As evident from FIG. 5, when the output of the oscillator is high, the switch Q1 is ON, and the transformer current iT begins to flow through the primary winding of the transformer TI Due to the large inductance of the transformer winding, the current iT linearly increases, as shown in FIG. 6. As soon as the current iT reaches a specified peak value, ipk, as sensed by the peak detector 162, the output of the oscillator is forced low, causing the switch Q1 to turn OFF.
As soon as the switch Q1 is turned OFF, the current iT sensed in the sensing resistor R1 goes to zero. However, the current flowing through the transformer winding cannot suddenly go to zero, but rather must ramp back down to zero. As it ramps back to zero it is referred to as the flyback current iF. The flyback current iF, as it ramps back to zero, starts at the same value as ipk. The diodes D1 and D2 provide a current path for the flyback current iF, and the presence of the current iF causes the voltage VT to increase above the battery voltage VBAT. As soon as the flyback current iF reaches zero, the voltage VT drops below the battery voltage VBAT. Hence, using the comparator 166, which compares VT to VBAT, a determination is easily made as to when the flyback current, which represents the transformer current and which also transfers energy to the output capacitors as long as it is non-zero, has gone to zero.
In accordance with the present invention, as soon as the transformer current reaches the programmed peak value, the switch Q1 is turned off, and the transformer current thereafter ramps back to zero. Energy is transferred to the output capacitor 56 as long as current is flowing in the primary winding of the transformer, whether such current is iT or iF. As soon as the transformer current reaches zero, which signifies the cessation of delivery of energy to the output capacitor, the oscillator is enabled so as to again turn the switch Q1 on, thereby starting the process over again. In this manner, there is very little dead time during which energy is not being transferred to the output capacitor 56, thereby reducing the time to charge the output capacitors.
As is evident from FIG. 6, by adjusting the programmable peak current reference value, ipk, it is possible to adjust the ON and OFF time of the oscillator so as to control the amount of energy transferred through the transformer T1 during each oscillator cycle. The oscillator 160 (which, as is evident from the above description, is not a free-running oscillator; but rather is a slave oscillator that produces a high output until the peak current is reached, whereupon it produces a low output until enabled by sensing that the transformer current has reached zero) preferably operates at a frequency above the audible range of humans, e.g., 25-50 kHz.
Returning to FIG. 5, it is seen that the control signals for controlling the switches S1-S5, labeled S1C-S5C, are all generated as controlled by the control/timing circuit 22. A transformer T4, for example, produces the control signal S5C for controlling the switch S5 at a secondary winding in response to a suitable control signal, S-5, applied to the primary winding of the transformer T4. The control signal S-5 is generated by the control/timing circuit 22 Advantageously, the control signals SIC and S4C are generated simultaneously by applying a single control signal S-1/4 to the primary winding of a transformer T2. Similarly, the control signals S2C and S3C are generated simultaneously by applying a single control signal S-2/3 to the primary winding of a transformer T3. Both the transformers T2 and T3 have two secondary windings, with one secondary winding controlling one switch, and the other secondary winding controlling the other switch. In this manner, only the appropriate switches on opposite sides of the "H" configuration of the switch network 58 can be turned on at one time, as is required to deliver the high voltage pulse to the heart in accordance with a desired polarity, and such result is achieved by using a single control signal, without any additional logic or control required.
As described above, it is thus seen that the present invention provides a tiered therapy ICD that advantageously affords a reduced time-to-therapy, thereby reducing the exposure of the patient to a tachyarrhythmia and increasing the probability of a successful cardioversion-defibrillation attempt.
It is also seen from the above description that the reduced time-to-therapy is provided by charging the high voltage output capacitors during the application of a less aggressive therapy, or while attempting to verify if a prior therapy attempt was successful, thereby allowing such capacitors to be fully charged and ready in the event a more aggressive therapy is needed.
As further described above, it is seen that the invention provides a charging circuit for charging one or more high voltage output capacitors within a tiered therapy ICD device, which charging circuit advantageously minimizes the time period required to obtain a prescribed charge on the high voltage output capacitors.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4398536 *Jul 17, 1981Aug 16, 1983Telectronics Pty. Ltd.Scanning burst tachycardia control pacerUS4427011 *Mar 18, 1982Jan 24, 1984Telectronics Pty. Ltd.Tachycardia control pacer with improved detection of tachycardia terminationUS4541430 *Oct 28, 1983Sep 17, 1985Siemens AktiengesellschaftMethod and a heart pacemaker for terminating a tachycardiaUS4739437 *Oct 22, 1986Apr 19, 1988Siemens-Pacesetter, Inc.Pacemaker output switch protectionUS4774952 *Oct 30, 1986Oct 4, 1988Medtronic, Inc.Cardioversion and defibrillation leadUS4809697 *Oct 14, 1987Mar 7, 1989Siemens-Pacesetter, Inc.Interactive programming and diagnostic system for use with implantable pacemakerUS4869252 *Jan 11, 1988Sep 26, 1989Telectronics N.V.Apparatus and method for controlling pulse energy in antitachyarrhythmia and bradycardia pacing deviceUS4895151 *Jul 20, 1987Jan 23, 1990Telectronics N.V.Apparatus and method for therapy adjustment in implantableUS4940052 *Jan 25, 1989Jul 10, 1990Siemens-Pacesetter, Inc.Microprocessor controlled rate-responsive pacemaker having automatic rate response threshold adjustmentUS4944299 *Aug 8, 1989Jul 31, 1990Siemens-Pacesetter, Inc.High speed digital telemetry system for implantable deviceUS4989602 *Apr 12, 1989Feb 5, 1991Siemens-Pacesetter, Inc.Programmable automatic implantable cardioverter/defibrillator and pacemaker systemUS4991603 *Oct 30, 1989Feb 12, 1991Siemens-Pacesetter, Inc.Transvenously placed defibrillation leads via an inferior vena cava access site and method of useUS4998975 *Oct 30, 1989Mar 12, 1991Siemens-Pacesetter, Inc.Travenously placed defibrillation leadsUS5103822 *Apr 3, 1990Apr 14, 1992Siemens-Pacesetter, Inc.Pacing system for termination of cardiac arrhythmias utilizing scanning techniquesUS5163427 *Nov 14, 1990Nov 17, 1992Medtronic, Inc.Apparatus for delivering single and multiple cardioversion and defibrillation pulses* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5584865 *Sep 26, 1994Dec 17, 1996Pacesetter AbDefibrillator with output stage using switching network and three electrodeUS5620467 *Oct 10, 1995Apr 15, 1997Incontrol, Inc.Implantable atrial defibrillator having cardioverting output voltage limiting for simulating larger storage capacitorsUS5620469 *Oct 11, 1994Apr 15, 1997Angeion CorporationStepped cardioversion system for an implantable cardioverter defibrillatorUS5700280 *May 3, 1996Dec 23, 1997Pacesetter, Inc.Method and apparatus for controlling the charging phase of an implantable cardioverter-defribrillatorUS5709710 *May 10, 1995Jan 20, 1998Armstrong; Randolph KerryImplantable cardioverter/defibrillator with adaptive shock coupling interval and methodUS5713924 *Jun 27, 1995Feb 3, 1998Medtronic, Inc.Defibrillation threshold reduction systemUS5772692 *Oct 29, 1996Jun 30, 1998Sulzer Intermedics Inc.Implantable medical device with automatic adjustment to externally generated shocksUS5792188 *Jan 23, 1997Aug 11, 1998Pacesetter, Inc.Capacitor reformation and measurement in an implantable cardioverter/defibrillator (ICD)US5830236 *Oct 29, 1996Nov 3, 1998Pacesetter, Inc.System for delivering low pain therapeutic electrical waveforms to the heartUS5836971 *Feb 26, 1997Nov 17, 1998Pacesetter, Inc.Dynamic rezoning of a tiered therapy inplantable cardioverter defibrillator/pacemaker (ICD) deviceUS5913878 *Feb 10, 1998Jun 22, 1999Angeion CorporationTiered therapy cardiac detection system having a global counterUS6295470Jan 14, 1999Sep 25, 2001The Mower Family Chf Treatment Irrevocable TrustAntitachycardial pacingUS6522920Dec 11, 2000Feb 18, 2003Pacesetter, Inc.System and method of protecting transformer-driven switches from external magnetic fieldsUS6704597 *Jul 20, 2000Mar 9, 2004Cardiac Pacemakers, Inc.Apparatus and method for energy management in atrial defibrillatorUS6718204 *Jul 30, 2001Apr 6, 2004Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS6856835 *Aug 27, 2001Feb 15, 2005Cameron Health, Inc.Biphasic waveform for anti-tachycardia pacing for a subcutaneous implantable cardioverter-defibrillatorUS6892094Apr 30, 2002May 10, 2005Medtronic, Inc.Combined anti-tachycardia pacing (ATP) and high voltage therapy for treating ventricular arrhythmiasUS6952610 *Nov 5, 2001Oct 4, 2005Cameron Health, Inc.Current waveforms for anti-tachycardia pacing for a subcutaneous implantable cardioverter- defibrillatorUS7149577Dec 2, 2002Dec 12, 2006Medtronic, Inc.Apparatus and method using ATP return cycle length for arrhythmia discriminationUS7151962 *Apr 29, 2004Dec 19, 2006Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS7181276 *Jul 27, 2004Feb 20, 2007Pacesetter, Inc.Device and method for preventing the acceleration of cardiac arrhythmiasUS7184831 *Apr 29, 2004Feb 27, 2007Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS7203537Jan 10, 2004Apr 10, 2007Mr3 Medical, LlcSystem and method for breaking reentry circuits by cooling cardiac tissueUS7203539Mar 5, 2004Apr 10, 2007Cardiac Pacemakers, Inc.Apparatus and method for energy management in atrial defibrillatorUS7277750Apr 2, 2004Oct 2, 2007Cardiac Pacemakers, Inc.Method and apparatus for anti-tachycardia pacing and defibrillationUS7282030Oct 15, 2003Oct 16, 2007Medtronic, Inc.Timed delay for redelivery of treatment therapy for a medical device systemUS7386344Aug 18, 2004Jun 10, 2008Cardiac Pacemakers, Inc.Pacer with combined defibrillator tailored for bradycardia patientsUS7440800May 31, 2005Oct 21, 2008Mr3 Medical, LlcSystem and method for managing detrimental cardiac remodelingUS7463924Jan 21, 2005Dec 9, 2008Cameron Health, Inc.Methods for determining placement of an implantable cardiac stimulus deviceUS7536222Nov 9, 2004May 19, 2009Cameron Health, Inc.Nonvascular implantable defibrillator and methodUS7580745Jan 18, 2005Aug 25, 2009Cardiac Pacemakers, Inc.Method and apparatus for using heart rate variability to control maximum tracking rate in pacing therapyUS7596410 *Apr 28, 2006Sep 29, 2009Pacesetter, Inc.Tiered antitachycardia pacing and pre-pulsing therapyUS7643877Feb 18, 2005Jan 5, 2010Cardiac Pacemakers, Inc.Cardiac rhythm management system with defibrillation threshold predictionUS7660629Nov 29, 2006Feb 9, 2010Pacesetter, Inc.Device and method for preventing the acceleration of cardiac arrhythmiasUS7672725 *Jan 18, 2005Mar 2, 2010Cardiac Pacemakers, Inc.Method and apparatus for using heart rate variability as a safety check in electrical therapiesUS7805189Jan 3, 2007Sep 28, 2010Medtronic, Inc.Voltage/current regulator improvements for an implantable medical deviceUS7840264Mar 30, 2007Nov 23, 2010Mr3 Medical, LlcSystem and method for breaking reentry circuits by cooling cardiac tissueUS7877138Sep 18, 2007Jan 25, 2011Cardiac Pacemakers, Inc.Method and apparatus for anti-tachycardia pacing and defibrillationUS7908003Jun 15, 2007Mar 15, 2011Mr3 Medical LlcSystem and method for treating ischemia by improving cardiac efficiencyUS8014858May 25, 2000Sep 6, 2011Impulse Dynamics N.V.Shockless defibrillationUS8036744Dec 7, 2009Oct 11, 2011Cardiac Pacemakers, Inc.Cardiac rhythm management system with defibrillation threshold predictionUS8055340 *May 5, 2005Nov 8, 2011Cardiac Pacemakers, Inc.Method and device for comprehensive anti-tachyarrhythmia therapyUS8131360Jan 17, 2011Mar 6, 2012Cardiac Pacemakers, Inc.Method and apparatus for anti-tachycardia pacing and defibrillationUS8170663 *Mar 16, 2007May 1, 2012Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS8224449Jun 29, 2009Jul 17, 2012Boston Scientific Neuromodulation CorporationMicrostimulator with flap electrodesUS8244371Mar 16, 2006Aug 14, 2012Metacure LimitedPancreas leadUS8260416Oct 31, 2007Sep 4, 2012Impulse Dynamics, N.V.Electrical muscle controllerUS8290585Jan 21, 2002Oct 16, 2012Mr3 Medical, LlcAugmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood poolUS8301247Oct 31, 2007Oct 30, 2012Impulse Dynamics, N.V.Electrical muscle controllerUS8306616Oct 31, 2007Nov 6, 2012Impulse Dynamics, N.V.Electrical muscle controllerUS8306617Oct 31, 2007Nov 6, 2012Impulse Dynamics N.V.Electrical muscle controllerUS8311629Oct 18, 2006Nov 13, 2012Impulse Dynamics, N.V.Electrical muscle controllerUS8321013 *Oct 31, 2007Nov 27, 2012Impulse Dynamics, N.V.Electrical muscle controller and pacing with hemodynamic enhancementUS8326416Oct 25, 2010Dec 4, 2012Impulse Dynamics NvApparatus and method for delivering electrical signals to modify gene expression in cardiac tissueUS8352031May 24, 2007Jan 8, 2013Impulse Dynamics NvProtein activity modificationUS8412320Aug 17, 2005Apr 2, 2013Cameron Health, Inc.Nontransvenous and nonepicardial methods of cardiac treatment and stimulusUS8412347Apr 29, 2009Apr 2, 2013Proteus Digital Health, Inc.Methods and apparatus for leads for implantable devicesUS8447399Apr 1, 2008May 21, 2013Mr3 Medical, LlcSystem and method for managing detrimental cardiac remodelingUS8452401Nov 2, 2011May 28, 2013Cardiac Pacemakers, Inc.Method and device for comprehensive anti-tachyarrhythmia therapyUS8473069Feb 27, 2009Jun 25, 2013Proteus Digital Health, Inc.Integrated circuit implementation and fault control system, device, and methodUS8478399 *Jan 31, 2006Jul 2, 2013Paul J. DegrootMethod and apparatus for controlling arrhythmia detection and treatment based on patient postureUS8548583May 4, 2006Oct 1, 2013Impulse Dynamics NvProtein activity modificationUS8644926Feb 12, 2013Feb 4, 2014Cameron Health, Inc.Subcutaneous defibrillator implantationUS8655444Oct 29, 2012Feb 18, 2014Impulse Dynamics, N.V.Electrical muscle controllerUS8666495Mar 18, 2005Mar 4, 2014Metacure LimitedGastrointestinal methods and apparatus for use in treating disorders and controlling blood sugarUS8700161Sep 4, 2003Apr 15, 2014Metacure LimitedBlood glucose level controlUS8706217Mar 30, 2012Apr 22, 2014Cameron HealthCardioverter-defibrillator having a focused shocking area and orientation thereofUS8712549Dec 11, 2003Apr 29, 2014Proteus Digital Health, Inc.Method and system for monitoring and treating hemodynamic parametersUS8718760May 6, 2013May 6, 2014Cameron Health Inc.Subcutaneous implantable cardioverter-defibrillator placement methodsUS8731658 *Jan 31, 2005May 20, 2014Physio-Control, IncSystem and method for using diagnostic pulses in connection with defibrillation therapyUS8761905 *Jun 4, 2012Jun 24, 2014Mirowski Family Ventures, L.L.C.Methods, apparatus, and systems for multiple stimulation from a single stimulatorUS8786049Jul 23, 2010Jul 22, 2014Proteus Digital Health, Inc.Solid-state thin-film capacitorUS8792985Jan 20, 2006Jul 29, 2014Metacure LimitedGastrointestinal methods and apparatus for use in treating disorders and controlling blood sugarUS8805503Feb 3, 2010Aug 12, 2014Cardiac Pacemakers, Inc.Method and apparatus for optimizing electrical stimulation parameters using heart rate variabilityUS8825152Apr 3, 2002Sep 2, 2014Impulse Dynamics, N.V.Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissueUS8831720Oct 25, 2013Sep 9, 2014Cameron Health, Inc.Method of implanting and using a subcutaneous defibrillatorUS8831724Jan 26, 2010Sep 9, 2014Cardiac Pacemakers, Inc.Method and apparatus for using heart rate variability as a safety check in electrical therapiesUS8934975Feb 1, 2011Jan 13, 2015Metacure LimitedGastrointestinal electrical therapyUS8958872Feb 17, 2014Feb 17, 2015Impulse Dynamics, N.V.Electrical muscle controllerUS8977353Aug 20, 2013Mar 10, 2015Impulse Dynamics NvProtein activity modificationUS9101765Feb 16, 2006Aug 11, 2015Metacure LimitedNon-immediate effects of therapyUS9138589Apr 4, 2014Sep 22, 2015Cameron Health, Inc.Apparatus and method for identifying atrial arrhythmia by far-field sensingUS9144683Oct 30, 2006Sep 29, 2015Cameron Health, Inc.Post-shock treatment in a subcutaneous deviceUS9149635 *Apr 27, 2012Oct 6, 2015Medtronic, Inc.Stimulation waveform generator for an implantable medical deviceUS9186514Feb 13, 2015Nov 17, 2015Impulse Dynamics NvElectrical muscle controllerUS9289618Oct 23, 2001Mar 22, 2016Impulse Dynamics NvElectrical muscle controllerUS9370665May 20, 2014Jun 21, 2016Physio-Control, Inc.System and method for using diagnostic pulses in connection with defibrillation therapyUS9440080Mar 9, 2015Sep 13, 2016Impulse Dynamics NvProtein activity modificationUS9522283Aug 27, 2015Dec 20, 2016Cameron Health Inc.Apparatus and method for identifying atrial arrhythmia by far-field sensingUS9566444May 8, 2014Feb 14, 2017Mirowski Family Ventures, L.L.C.Methods, apparatus, and systems for multiple stimulation from a single stimulatorUS20020035376 *Aug 27, 2001Mar 21, 2002Cameron Health, Inc.Biphasic waveform for anti-tachycardia pacing for a subcutaneous implantable cardioverter-defibrillatorUS20020095184 *Nov 5, 2001Jul 18, 2002Bardy Gust H.Monophasic waveform for anti-tachycardia pacing for a subcutaneous implantable cardioverter-defibrillatorUS20020099413 *Jan 21, 2002Jul 25, 2002Mower Morton M.Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood poolUS20020120299 *Nov 5, 2001Aug 29, 2002Cameron Health, Inc.Current waveforms for anti-tachycardia pacing for a subcutaneous implantable cardioverter- defibrillatorUS20030204210 *Apr 30, 2002Oct 30, 2003Ousdigian Kevin T.Combined anti-tachycardia pacing (ATP) and high voltage therapy for treating ventricular arrhythmiasUS20030208244 *Apr 26, 2002Nov 6, 2003Medtronic, Inc.Voltage/current regulator improvements for an implantable medical deviceUS20040106956 *Dec 2, 2002Jun 3, 2004Vinod SharmaApparatus and method using ATP return cycle length for arrhythmia discriminationUS20040152958 *Oct 15, 2003Aug 5, 2004Medtronic, Inc.Timed delay for redelivery of treatment therapy for a medical device systemUS20040181259 *Mar 26, 2004Sep 16, 2004Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS20040193021 *Dec 11, 2003Sep 30, 2004Proteus Biomedical, Inc., A Delaware CorporationMethod and system for monitoring and treating hemodynamic parametersUS20050027318 *Mar 5, 2004Feb 3, 2005Cardiac Pacemakers, Inc.Apparatus and method for energy management in atrial defibrillatorUS20050065559 *Nov 9, 2004Mar 24, 2005Cameron Health, Inc.Monophasic waveform for anti-tachycardia pacing for a subcutaneous implantable cardioverter-defibrillatorUS20050137637 *Jan 21, 2005Jun 23, 2005Cameron Health, Inc.Biphasic waveform for anti-tachycardia pacing for a subcutaneous implantable cardioverter-defibrillatorUS20050222629 *Apr 2, 2004Oct 6, 2005Perschbacher David LMethod and apparatus for anti-tachycardia pacing and defibrillationUS20050245979 *Apr 29, 2004Nov 3, 2005Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS20050245980 *Apr 29, 2004Nov 3, 2005Medtronic, Inc.Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS20050251215 *Feb 18, 2005Nov 10, 2005Dujmovic Richard M JrCardiac rhythm management system with defibrillation threshold predictionUS20050277990 *Aug 17, 2005Dec 15, 2005Cameron Health, Inc.Current waveforms for anti-tachycardia pacing for a subcutaneous implantable cardioverter-defibrillatorUS20050277993 *May 31, 2005Dec 15, 2005Mower Morton MSystem and method for managing detrimental cardiac remodelingUS20060004424 *Jun 6, 2005Jan 5, 2006University Of Southern CaliforniaCharge-metered biomedical stimulatorUS20060036288 *Aug 18, 2004Feb 16, 2006Bocek Joseph MPacer with combined defibrillator tailored for bradycardia patientsUS20060161209 *Jan 18, 2005Jul 20, 2006Cardiac Pacemakers, Inc.Method and apparatus for using heart rate variability as a safety check in electrical therapiesUS20060161210 *Jan 18, 2005Jul 20, 2006Cardiac Pacemakers, Inc.Method and apparatus for using heart rate variability to control maximum tracking rate in pacing therapyUS20060173499 *Jan 31, 2005Aug 3, 2006Medtronic Emergency Response Systems, Inc.System and method for using diagnostic pulses in connection with defibrillation therapyUS20060253157 *May 5, 2005Nov 9, 2006Imad LibbusMethod and device for comprehensive anti-tachyarrhythmia therapyUS20060265017 *May 31, 2005Nov 23, 2006Mower Morton MSystem and method for managing detrimental cardiac remodelingUS20070088393 *Oct 18, 2006Apr 19, 2007Shlomo Ben-HaimElectrical Muscle ControllerUS20070088395 *Nov 29, 2006Apr 19, 2007Pacesetter, Inc.Device and method for preventing the acceleration of cardiac arrhythmiasUS20070156177 *Dec 27, 2006Jul 5, 2007Impulse Dynamics N.V.Blood glucose level controlUS20070156189 *Mar 16, 2007Jul 5, 2007Degroot Paul JMethod and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceUS20070162079 *Feb 12, 2007Jul 12, 2007Shemer Isaac YitzhakSignal Delivery Through The Right Ventricular SeptumUS20070179539 *Jan 31, 2006Aug 2, 2007Degroot Paul JMethod and apparatus for controlling arrhythmia detection and treatment based on patient postureUS20070179569 *Mar 29, 2007Aug 2, 2007Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS20070191907 *Jan 3, 2007Aug 16, 2007Medtronic, Inc.Voltage/current regulator improvements for an implantable medical deviceUS20070270911 *Mar 30, 2007Nov 22, 2007Thomas DoerrHeart stimulatorUS20080009906 *Sep 18, 2007Jan 10, 2008Cardiac Pacemakers, Inc.Method and apparatus for anti-tachycardia pacing and defibrillationUS20080065159 *Oct 31, 2007Mar 13, 2008Shlomo Ben-HaimElectrical Muscle ControllerUS20080065164 *Oct 31, 2007Mar 13, 2008Shlomo Ben-HaimElectrical Muscle ControllerUS20080243201 *Jun 9, 2008Oct 2, 2008Cardiac Pacemakers, Inc.Pacer with combined defibrillator tailored for bradycardia patientsUS20080273784 *May 1, 2008Nov 6, 2008Marcus PfisterImage system for retaining contrast when merging image dataUS20080287855 *Apr 1, 2008Nov 20, 2008Mower Morton MSystem and method for managing detrimental cardiac remodelingUS20090131993 *Feb 16, 2006May 21, 2009Benny RoussoNon-Immediate Effects of TherapyUS20090287266 *May 12, 2009Nov 19, 2009Mark ZdeblickHigh-voltage tolerant multiplex multi-electrode stimulation systems and methods for using the sameUS20090299447 *Jun 30, 2006Dec 3, 2009Marc JensenDeployable epicardial electrode and sensor arrayUS20100094368 *Dec 9, 2009Apr 15, 2010Johns Hopkins UniversitySystem and/or method for refibrillation of the heart for treatment of post-countershock pulseless electrical activity and/or asystoleUS20100131026 *Jan 26, 2010May 27, 2010Pastore Joseph MMethod and apparatus for using heart rate variability as a safety check in electrical therapiesUS20100137932 *Feb 3, 2010Jun 3, 2010Pastore Joseph MMethod and apparatus for optimizing electrical stimulation parameters using heart rate variabilityUS20100249883 *Mar 11, 2010Sep 30, 2010Proteus Biomedical, Inc.Methods for Configuring Satellite ElectrodesUS20100318163 *Apr 29, 2009Dec 16, 2010Mark ZdeblickMethods and apparatus for leads for implantable devicesUS20100331933 *Jun 29, 2009Dec 30, 2010Boston Scientific Neuromodulation CorporationMicrostimulator with flap electrodesUS20110118798 *Jan 17, 2011May 19, 2011Perschbacher David LMethod and apparatus for anti-tachycardia pacing and defibrillationUS20120253418 *Jun 4, 2012Oct 4, 2012Mirowski Family Ventures, L.L.C.Methods, apparatus, and systems for multiple stimulation from a single stimulatorUS20130289658 *Apr 27, 2012Oct 31, 2013Medtronic, Inc.Stimulation wafeform generator for an implantable medical deviceDE102006023517A1 *May 19, 2006Nov 22, 2007Biotronik Crm Patent AgHerzstimulatorWO1996011035A1 *Oct 10, 1995Apr 18, 1996Angeion CorporationStepped cardioversion system for an implantable cardioverter defibrillatorWO2003011391A3 *Jul 25, 2002Oct 16, 2003Medtronic IncMethod and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical deviceWO2004050181A1Dec 1, 2003Jun 17, 2004Medtronic, Inc.Apparatus and method using atp return cycle length for arrhythmia discriminationWO2009131749A2 *Feb 27, 2009Oct 29, 2009Proteus Biomedical, Inc.Integrated circuit implementation and fault control system, device, and methodWO2009131749A3 *Feb 27, 2009Jan 7, 2010Proteus Biomedical, Inc.Integrated circuit implementation and fault control system, device, and method* Cited by examinerClassifications U.S. Classification607/5, 607/7International ClassificationA61N1/362, A61N1/39Cooperative ClassificationA61N1/3962European ClassificationA61N1/39M2Legal EventsDateCodeEventDescriptionNov 23, 1992ASAssignmentOwner name: SIEMENS AKTIENGESELLSCHAFT, GERMANYFree format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CAUSEY, JAMES D. III;MANN, BRIAN M.;REEL/FRAME:006330/0260Effective date: 19921120Owner name: SIEMENS PACESETTER, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CAUSEY, JAMES D. III;MANN, BRIAN M.;REEL/FRAME:006330/0260Effective date: 19921120Owner name: SIEMENS-ELEMA AB, SWEDENFree format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CAUSEY, JAMES D. III;MANN, BRIAN M.;REEL/FRAME:006330/0260Effective date: 19921120Mar 23, 1995ASAssignmentOwner name: PACESETTER, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIEMENS PACESETTER, INC.;REEL/FRAME:007388/0042Effective date: 19940930Sep 25, 1997FPAYFee paymentYear of fee payment: 4Dec 6, 2001FPAYFee paymentYear of fee payment: 8Dec 7, 2005FPAYFee paymentYear of fee payment: 12RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services